Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025Business Wire • 10/15/25
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTGlobeNewsWire • 09/24/25
HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025Business Wire • 09/24/25
Summit Therapeutics Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. September 24, 2025 Deadline to file Lead Plaintiff Motion.GlobeNewsWire • 09/09/25
SMMT Stock Plummets 25% on Regional Data Differences in NSCLC StudyZacks Investment Research • 09/09/25
Summit Therapeutics shares fall as lung cancer trial results disappointProactive Investors • 09/08/25
Summit Therapeutics Crashes After Failing To Deliver Another Merck-Walloping PunchInvestors Business Daily • 09/08/25
Summit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data DifferencesBenzinga • 09/08/25
New Fortress Energy Posts Q2 Loss, Joins Summit Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market SessionBenzinga • 09/08/25
Ivonescimab Plus Chemotherapy Demonstrates Consistent Global Benefit: HARMONi Data Update Shows OS HR=0.78, Nominal P=0.0332PRNewsWire • 09/07/25
Longer-Term Follow-Up of Western Patients Showed Improving, Favorable Trend in Overall Survival in Global Phase III HARMONi Clinical Trial for Ivonescimab Plus Chemotherapy in 2L+ EGFRm NSCLCBusiness Wire • 09/07/25
Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck's Keytruda Multi-Billion Dollar Franchise, Says AnalystBenzinga • 08/27/25
Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025Business Wire • 08/14/25